Top Banner
Neonatal Septic shock Safaa A. EL Meneza Professor of Pediatrics Faculty of Medicine for Girls AL Azhar University
124

Final Mansoura April 2-4.2009

May 30, 2018

Download

Documents

lordoftheweb
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 1/124

Neonatal Septic

shock 

Safaa A. EL Meneza

Professor of Pediatrics

Faculty of Medicine for

GirlsAL Azhar University

Page 2: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 2/124

Objectives Definitions Epidemiology Pathophysiology

Management of septicshock

Prevention

Page 3: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 3/124

Direct Causes of NeonatalDeaths

  Infections 32%

Asphyxia 29%

Complications of prematurity24% Congenital anomalies 10%

Other 5%

World Health Organization.State of the World’s Newborns 2005

Page 4: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 4/124

Septic shock  Diagnosis and treatment

of neonatal septic shock are quite difficult as :

Page 5: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 5/124

Septic shock  The hyperdynamic phase

of septic shock innewborns can be short. VLBW may have acute

hypotension ,bradycardiawithout precedingtachycardia

Page 6: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 6/124

Septic shock 

2. Sepsis is a clinical

diagnosis and does notrely on early isolation of the causative infectiousorganism .

Page 7: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 7/124

ac er a so a es nneonatal sepsis in NICUs

in Egypt Bakr AF. J Trop Pediatrics 2003 

45 cases of neonatal sepsis Klebsiella 78%, E. coli 11%, Candida 

6.6%, Pseudomonas 4.4% Moore KL, Kainer MA, Badrawi N,et

al. Pediatr Inf Dis J. 2005 33 infants with clinical sepsis 21 (64%) blood cultures + < 24 hours after

birth Klebsiella 80%, Enterobacter 10%, E.coli 

6%,

Acinetobacter 3%.

Page 8: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 8/124

Bacterial isolates in neonatal

sepsis in NICUs in Egypt In NICU of AL Zhraa University

hospitalwe found that gram negative in55% of cases ; K. pneumoniae , Ecoli, enterobactr spp, citrobacterspp and serratia m.

K. pneumoniae phenotyping and

genotyping showedmacrorestriction profiles of chromosomal DNA of 15 distinctpatterns.

Abd ELHalim N. MD thesis 2009 ,supervised by Aly G.,ELMeneza S. and EL salakawy A. , FMG , AL Azhar University

Page 9: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 9/124

Not a single pathologic

entity!

What is septic shock

Page 10: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 10/124

DEFINITIONS

Page 11: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 11/124

Page 12: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 12/124

Septic shock 

Sepsis andcardiovascular

organ dysfunction

Goldstein et.al Pediatr crit care Med 2005 Vol.6 No.1

Page 13: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 13/124

Decrease in BP

< 5th percentile for age or

systolic BP <  2 SD belownormal for age

No response toadministration of isotonicintravenous fluid bolus ≥40

mL/kg in 1 hr OR

● Cardiovasculardysfunction

Goldistein et al Ped.cri.car.Med.6,1,2oo5

Page 14: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 14/124

● Cardiovascular

dysfunction 

Need for vasoactive drug to

maintain BP in normal range(dopamine > 5 u/kg/min ordobutamine, epinephrine, or

nor epinephrine at any dose)

 

Goldistein et al Ped.cri.car.Med.6,1,2oo5

Page 15: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 15/124

Septic shock  Septic shock is caused

byan acute failure of  circulatory function and 

is characterized byinadequate tissue andorgan perfusion.

Page 16: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 16/124

Page 17: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 17/124

Septic Shock  Septic shock is a

subclassof distributive shock commonly associated

with bacterial and viralinfections in neonates.

Page 18: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 18/124

Septic Shock  The hallmark of septic

shock is markedprogressive hypotension frequently refractory to

therapy .

Page 19: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 19/124

Page 20: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 20/124

Page 21: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 21/124

SEPSIS-SEPTIC SHOCK CONSIDERATIONS

 There are a number of well known host-related risk factors for sepsis. Theyinclude:

Extremes of age A compromised immune system Malnourishment Asplenia Chronic antibiotic or steroid use Additionally, any insult (shock, trauma,

burn) that makes the gastrointestinaltract permeable to gram negative

bacteria puts individuals at risk for gramne ative se sis

Page 22: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 22/124

SEPSIS-SEPTIC SHOCK CONSIDERATIONS

Genetic polymorphisms Inflammatory cell function

Endothelial activation and injury Coagulation and fibrin deposition Vasodilatory shock Vasopresin

Hipothalamic-pituitary-adrenal axis Cardiac dysfunction  Tissue oxygenation and perfusion

SEPSIS SEPTIC SHOCK

Page 23: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 23/124

SEPSIS-SEPTIC SHOCK CONSIDERATIONS

Genetic polymorphisms

 TNF- polymorphism (hypersecretion) LPS-binding protein alleles IL-1  Toll-like receptor 4

Frequency and survival Variability in septic course Response to therapy Outcome

Page 24: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 24/124

SEPSIS-SEPTIC SHOCK CONSIDERATIONS

Inflammatory cell function

Low monocyte count (CD13) IL-12 IL-8

Greater risk of death

SEPSIS SEPTIC SHOCK CONSIDERATIONS

Page 25: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 25/124

SEPSIS-SEPTIC SHOCK CONSIDERATIONS

Vasodilatory shock

Page 26: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 26/124

Septic Shock 

Septic shock  

characterized byarteriolar and venousvasodilatation

that results in lowsystemic vascularresistance despite initial

Page 27: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 27/124

Hypothalamic-pituitary-adrenalaxis

•Relative adrenal insufficiency•Corticotrophin resistance +

•Reduced adrenal glucocorticoids

synthesisLonger length of stay and more

organ dysfunction

SEPSIS-SEPTIC SHOCK 

CONSIDERATIONS

Page 28: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 28/124

Page 29: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 29/124

Cardiac dysfunction

Page 30: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 30/124

  There is significant There is significant

decrease in thedecrease in themyocardial contractilitymyocardial contractilityamong the newborn infantamong the newborn infant

suffered from septic shocksuffered from septic shockEL Meneza S,et al . Perinatology,Vol 21,No 7

505-06(Abs)2001

Cardiac dysfunction

Page 31: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 31/124

Page 32: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 32/124

-Cardiac dysfunctionthrough uncoupling of 

β adrenergeic receptors&

by direct inhibition of intracellular calcium

homeostasis

Page 33: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 33/124

Newborn infants have alsodysfunction due toimmaturity of myocardium

Abnormal peripheral

vasoregulation due to“immaturity of autonomicnervous system”

Cardiac dysfunction

Page 34: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 34/124

Cardiac dysfunction

Lopez preceedings ICP conference2007

Page 35: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 35/124

Septic Shock

Lopez preceedings ICP conference2007

Page 36: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 36/124

Page 37: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 37/124

Septic Shock

Page 38: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 38/124

Page 39: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 39/124

Page 40: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 40/124

Page 41: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 41/124

Page 42: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 42/124

Page 43: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 43/124

We found significantincrease in No in newborninfants with sepsis shock

EL Meneza S,et. al. Perinatology. 21, 7,505-06 (Abs)2001

Page 44: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 44/124

Page 45: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 45/124

Cytokines TNFα, IL-1β, IL-6released in a large scale

inflammatory responseresults in massivevasodilation, increasedcapillary permeability,decreased systemicvascular resistance, andhypotension.Kumar, et al .. (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier. pp. 102-103

Inflammatory mediators and

Page 46: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 46/124

Ware and Matthay NEJM 342 (18): 1334

Inflammatory mediators andcapillary leak syndrome

Page 47: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 47/124

Page 48: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 48/124

In MD study,in our unit wecould found significant

decrease of APC, protein c,antithrombin III among septic

newborn than the controlgroup

EL GandyEL Gandy MD, MD thesis,Supervised by ELMeneza S.ELMahdy M, FMG, AL Azhar University, 1997

Protein C Activated Protein C

SEPSIS-SEPTIC SHOCK CONSIDERATIONS

Page 49: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 49/124

SEPSIS SEPTIC SHOCK CONSIDERATIONSEndothelial activation

Coagulation and fibrin deposition

Page 50: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 50/124

Micro thrombusformation

Page 51: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 51/124

Page 52: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 52/124

Page 53: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 53/124

Page 54: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 54/124

Pseudomonas sepsis withDIC

J Evans et al, Clin Therapeutics, 2006

Page 55: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 55/124

Invasive Candidiasis

J Evans et al, Clin Therapeutics, 2006

id th t th

Page 56: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 56/124

 consider that there are:

1-Maldistribution of circulatoryvolume

2-Depressed myocardialfunction

3-Hypoxic hypoxia  -Diminished oxygen delivery

-A decrease in the number of functionalcapillaries causes an inability to extract oxygenmaximally

-There is inability of the erythrocytes to

Page 57: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 57/124

3-Direct cytotoxicity

This is called cytopathic

or histotoxic anoxia an inability to utilize oxygen

even when it is present

Page 58: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 58/124

4-Apoptosis

The proinflammatorycytokines

may delay  apoptosis inactivated

macrophages and neutrophilsbutother tissues such as gut

epithelium, may undergo

5

Page 59: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 59/124

5-Immunosuppression

The interaction betweenproinflammatory

andanti-inflammatory mediators

may lead to an imbalance

Page 60: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 60/124

It is currently believed that if pro-inflammatory predominate

an inflammatory cascadeensues ,and immediate

pathophysiologicprocesses are initiated

Page 61: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 61/124

Page 62: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 62/124

Page 63: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 63/124

Septic shock

Signs of early septic shockmay be subtle and there is a

danger of overlooking them ina busy emergency department.

 The patient may not always

adhere to the classic stages of shock described in textbooks.

Page 64: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 64/124

Pallor

poor skinperfusion

Page 65: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 65/124

1-Pallor and poor skinperfusion2-Capillary refill >2 sec2-Cool extremities

3-CNS dysfunction4-Decreased urine output

Page 66: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 66/124

Page 67: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 67/124

TREATMENT

The recommendations for

support of term newbornsand children are primarilyexpert opinion rather than

irrefutable evidence due tolack of RCT

Thus -state –of- the art

Page 68: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 68/124

Thus -state –of- the art management 

1- Haemodynamicresuscitation and organ

support Adequate blood flow Preserve organ perfusion and

regional distribution of total cardiacoutput

Preserve vascular beds:

integrity and vasomotor tone

Thus -state –of- the art

Page 69: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 69/124

Thus -state –of- the art management 

2- Eradicate infection Early recognition Early and adequate antibiotic

therapy Source control

Thus -state –of- the art

Page 70: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 70/124

Thus -state –of- the art management 

3- Sustained support Minimizing iatrogenic injury Ventilation,Haemoglobin,

Glucose

  4- Modulation of inflammatory response Coagulation, adrenal response

RESUSCITATION OF

Page 71: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 71/124

RESUSCITATION OFPEDIATRIC SEPTIC SHOCK 

Page 72: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 72/124

Page 73: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 73/124

Page 74: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 74/124

First Hour of Resuscitation

(Level III) 

Page 75: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 75/124

Push 10 cc/kg isotonic

Page 76: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 76/124

-Push 10 cc/kg isotoniccrystalloid

or colloid boluses to 60cc/kg

-Correct hypoglycemia &

hypocalcaemia 

-Begin prostaglandin infusion

until echocardiogramshows no dependentlesion

Page 77: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 77/124

It is important to distinguishnewborn septic shock from

cardiogenic shock caused byclosure of the PDA innewborns with ductal

dependent complexcongenital heart disease

Page 78: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 78/124

15 min

Fluid responsive

Observe in NICU

Page 79: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 79/124

15 minFluid refractory shock 

-Establish central venousand arterial access

-Titrate dopamine/ anddobutamine

Page 80: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 80/124

Homodynamic Support

(Level II)Although dopamine can be

used as the first-line agentits effect on pulmonary vascular resistance 

should be taken into account

A I t th bl ???

Page 81: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 81/124

Are Inotropes the problem???

Pressor medication certainly play an importantrole in shock, but

Use of pressors such as dopamine could be worse

than mild hypotension itself, particularly when notclose monitoring and control of BP

 There may be place for permissivehypotension, particularly when low BP is the

only symptom….may be better to watch andwait than to jump inAl-Aweel J Perinatology 2001

Are Inotropes the problem??

Page 82: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 82/124

p pAbstract, PAS 2007

Infants who were stillreceived inotropes after

being normotensive, weremore likely to have asevere IVH (18%) than

hypotensive infants whodid not receive inotropes(6%)J Evans et al, Clin Therapeutics, 2006

Page 83: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 83/124

Page 84: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 84/124

Fluid refractory- dopamineresistant shock 

- Titrate epinephrine-Systemic-alkalinization if 

PPHN and acidosis ispresent

Page 85: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 85/124

Phenomenon of non

responding tovasopressor during shock

is due to decrease sensitivity

to dopamine due to

Page 86: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 86/124

1-Down regulation of βadrenergic receptors

2-Decrease in expressionof adrenergenic receptorsin critically ill neonates

3-Immaturity as depletedmyocardial nor epinephrine stores

Zhang 1999

Page 87: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 87/124

60 min

Catecholamine - resistantshock 

Direct therapies usingechocardiogram, arterial

and CVPmonitoring

Page 88: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 88/124

60 minCatecholamine resistant shock

Page 89: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 89/124

Cold shockNormal blood pressurePoor LV function

Central venous O2 sat < 70%

 Titrate vasodilator or

type III PDE inhibitor withvolume loading

Catecholamine - resistant shock 

60 minCatecholamine - resistant shock

Page 90: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 90/124

Cold or warm shockPoor RV functionPPHN

Central venous O2 sat<70%

Inhaled nitric oxide

60 min

Page 91: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 91/124

Warm shockLow blood pressure

  Titrate volume and

epinephrine

60 minCatecholamine - resistant shock

Page 92: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 92/124

Refractory shock

 

ECMO

What drug should we use?

Page 93: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 93/124

What drug should we use?

In general when blood pressure is low in a sickneonate, dopamine is more effective thandobutamine* in raising blood pressure and increasingsystemic vascular resistance probably best to use if 

low BP but normal cardiac function If myocardial performance is impaired, the addition

of dobutamine may be beneficial as it has moreeffect on left ventricular output; Dobutamine, used

without an alpha- adrenergic medication, may wellcause worsened hypotension…but still can improveorgan perfusion

Epinephrine increases both cardiac output and blood

pressure: best to use when blood pressure and

Therapeutic End Points

Page 94: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 94/124

Therapeutic End Points(Level III)

 Therapeutic end points include:• Capillary refill of < 2 secs

•Normal pulses with nodifferential between

peripheral and central pulses•Warm extremities,•Urine output of > 1 mL/kg/hr

Page 95: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 95/124

Therapeutic End Points

•Normal mental status•Normal blood pressure for age

•Difference in preductal andpostductal oxygen saturation of  

< 5%

and• Oxygen saturation of > 95%

•Increase pH and decrease lactate

Activities

Page 96: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 96/124

Activities

A. Initial Resuscitation

B. Diagnosis

C. Antibiotic TherapyD. Source Control

F. Use Vasopressors

G. Inotropic Therapy

H. Steroids

 J. Blood Product Administration

Activities

Page 97: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 97/124

K. Mechanical Ventilation of sepsis

Induced Acute Lung Injury (ALI)/AR

L. Sedation, Analgesia, and neuromus

Blockade in sepsis

M. Glucose Control

N. Renal Replacement

Activities

Page 98: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 98/124

Stabilization: Beyond the

First HourLevel (III)

Goals

Page 99: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 99/124

Goals

*Maintain threshold heart rate*Maintain normal perfusion and

blood pressure*Maintain neonatal circulation

Central venous oxygensaturation > 70%

Steroids

Page 100: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 100/124

Steroids

When

Should be used??????

SCHEMATIC SUMMARY OF GLUCOCORTICOIDPROPERTIES

Page 101: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 101/124

PROPERTIES

Carcillo,task force.Shock,

20(3):197-207,2003

 Glucocorticoids in Neonatal

Page 102: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 102/124

Shock ?

Some known effects Upregulation of beta-

adrenergic receptors Increased concentrations of 

catecholamines

Improvement in capillaryintegrity

Direct inotropic effect on

myocytes-increased

Page 103: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 103/124

Carcillo,Task force.Shock,20(3):197-207,2003

Page 104: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 104/124

Page 105: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 105/124

Current Immune therapyCurrent Immune therapy

1-Immunoglobulin1-Immunoglobulin

2-Granulocytes infusions2-Granulocytes infusions3-Double volume exchange3-Double volume exchange

transfusionstransfusions4-rhu-GM-CSF4-rhu-GM-CSF

Granulocyte MacrophageC l S i l i

Page 106: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 106/124

Colony Stimulating Factor

Page 107: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 107/124

Page 108: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 108/124

Break the chain of 

inflammation /tissueinjury

Page 109: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 109/124

Emphasized that nosingle therapy would bebeneficial for all patient

with sepsis

G hG th

Page 110: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 110/124

SomeSome patient may benefit frompatient may benefit from

i.e. microbial challenge is morei.e. microbial challenge is moreeffectively clearedeffectively cleared

Gene therapyGene therapy

Page 111: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 111/124

OtherOther will benefit fromwill benefit from

i.e. reduce the cascade of i.e. reduce the cascade of inflammatory mediatorsinflammatory mediators

Gene therapyGene therapy

Page 112: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 112/124

Immune TherapyImmune Therapy

Page 113: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 113/124

Monoclonal antibodies againsttumour necrosis factor

Blockade of eicosanoidproduction

Blockade IL-1 activity Inhibition of nitric oxide

synthaseExogenous surfactant

High Mobility Group

Page 114: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 114/124

g y pBox Protein 1

•Nuclear protein bind DNAstabilize nucleosomes

•Extracellular mediator insystemic inflammation

•Could be therapeutic target inmanagement of sepsis

 Triggering receptor expressed on

Page 115: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 115/124

myeloid cells

•Activates neutrophils andmonocytes/macrophages

 

•Amplifies TLRs responsesagainst

microbial challenges

Toll-Like receptors

Page 116: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 116/124

 Toll Like receptors

•Modulate the inflammatoryresponse

Variable expression(neutrophils, dendritic cells, etc.)

Controlling or modifying :

septic process 

 The future strategy will

Page 117: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 117/124

1-Immunophenotype of patients

2-Prediction of host responseto disease and therapy

Wheeler et al Pediatr Crit Care Med 2001;2: 299-310

gyrelay on

Page 118: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 118/124

Dellinger RP, Levy MM, Carlet JM, et al: Surviving SepsisCampaign: Guidelines for management of severe sepsis andseptic shock. Intensive Care Medicine (2008).

Page 119: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 119/124

Simple interventions

Page 120: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 120/124

Simple interventionsthat work

Hand washing and asepticprecautions

Enteral nutrition Strict antibiotic policy Nursing training and involvement

of nurses in decision making andadministrative issues

Involvement of mothersAgarwal et al. J Perinatol 2007

REFERENCES1-Wheeler DS,WongHR.The impact of molecular

Page 121: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 121/124

g pbiology on the practice of pediatric critical care

medicine. Pediatr Crit Care Med 2001;2: 299-3102-Collins FS,Mckusick VA.Implications of the human

genome project for medical science.JAMA2001;285:540-544

3-Levin M,Qunit PA,Goldstein B.Recombinant

bactericidal/permeability increasing protein(eBPI21)as adjunctive treatment for children with severemeningococcal sepsis :A randomized trial.Lancet

2000;356:961-967

4-SchmidtsSM,Murphy C,While R.APC inhibits TNF andMIF production in monocytes.Eur Cytokine Netw2000;11:407-413.

5-Brett P.G.septic shock :beyond antibiotics.AAPmeeting syllabus 1996

h d i d h b

Page 122: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 122/124

6- S.A.EL MENEZA,N A .Khodeir and SS KhattabSignificance of platelet derived growth factor- AB and

nitric oxide in newborns Suffering from perinatal asphyxiaStudy II:Relation to cerebral blood flow Perinatal Med

vol29, suppl 1 2001,1227-EL Meneza S,Khalil O.Aly E .Necrotizing enterocolitis,

early detection and Prevention.Hot topics 98 InNeonatology,Washington DC,December 6-8.1998Proceeding Page 483 -485

8-S.A.EL MENEZA,N A .Khodeir and SS Khattab.J.Significance platelet-derived growth factor-AB and nitric

oxide in newborn infants suffering from perinatalasphyxia. Perinatology,Vol 21,No 7,505-06(Abs)2001

Page 123: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 123/124

9-EL Meneza S,Khalil O .Study of the impact of 

nosocomial infection on mortality and morbidity of ventilated newborn infants. Hot topic IN Neonatology,Washington DC December 5-7,1999 .Proceeding,424-425

10-EL Gandy M,EL Meneza S,EL Mahdy M and Nasef S.Study of some risk factors for hypercoagulation andthrombosis in newborn MD,thesis,AL Azhar University

199711-Sheata K,Refaie F,EL Meneza S and Esmat A.

Biochemical Study on ICAM among neonates with

PA,b.Sc Aim Shamas 1995

شكرا

Page 124: Final Mansoura April 2-4.2009

8/14/2019 Final Mansoura April 2-4.2009

http://slidepdf.com/reader/full/final-mansoura-april-2-42009 124/124